Business Standard

Saturday, February 15, 2025 | 11:09 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Pricing trend, launches, stability of growth boosters for Dr Reddy's

Near-term outlook and valuation are expected to support the stock price

Dr Reddy’s, Labs
Premium

Ram Prasad Sahu
Dr Reddy's, India's third-largest listed pharmaceutical company by market capitalisation, posted a steady performance for the December quarter. Barring Europe, which saw a decline, most key markets posted YoY growth in the quarter, leading to 8 per cent growth in consolidated revenues. 

Among the top performers were the emerging markets, which reported a 20 per cent jump; the proprietary business gained 37 per cent. Within emerging markets, the rest of the world segment saw sharp 46 per cent growth aided by product launches and higher sales volumes for the base business. The emerging markets business of Dr Reddy’s is the second-largest

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in